Author:
Hafeez Amna,Shabbir Maria,Khan Khushbukhat,Trembley Janeen H.,Badshah Yasmin,Zafar Sameen,Shahid Kanza,Shah Hania,Ashraf Naeem Mahmood,Hamid Arslan,Afsar Tayyaba,Almajwal Ali,Marium Afifa,Razak Suhail
Abstract
Abstract
Background
Single nucleotide polymorphisms (SNPs) have been linked with prostate cancer (PCa) and have shown potential as prognostic markers for advanced stages. Loss of function mutations in PKCι have been linked with increased risk of malignancy by enhancing tumor cell motility and invasion. We have evaluated the impact of two coding region SNPs on the PKCι gene (PRKCI) and their prognostic potential.
Methods
Genotypic association of non-synonymous PKCι SNPs rs1197750201 and rs1199520604 with PCa was determined through tetra-ARMS PCR. PKCι was docked with interacting partner Par-6 to determine the effect of these variants on PKCι binding capabilities. Molecular dynamic simulations of PKCι docked with Par-6 were performed to determine variant effects on PKCι protein interactions. The possible impact of changes in PKCι protein interactions on epithelial cell polarity was hypothesized.
Results
PKCι rs1199520604 mutant genotype TT showed association with PCa (p = 0.0055), while rs1197750201 mutant genotype AA also showed significant association with PCa (P = 0.0006). The binding interaction of PKCι with Par-6 was altered for both variants, with changes in Van der Waals energy and electrostatic energy of docked structures.
Conclusion
Genotypic analysis of two non-synonymous PKCι variants in association with PCa prognosis was performed. Both variants in the PB1 domain showed potential as a prognostic marker for PCa. In silico analysis of the effect of the variants on PKCι protein interactions indicated they may be involved in PCa progression through aberration of epithelial cell polarity pathways.
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2021;71(3):209–49.
2. Allemailem KS, Almatroudi A, Alrumaihi F, Almansour NM, Aldakheel FM, Rather RA, et al. Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics. Am J Transl Res. 2021;13(4):3868.
3. Benafif S, Kote-Jarai Z, Eeles RA. A review of prostate cancer genome-wide association studies (GWAS). Cancer Epidemiol Prev Biomarkers. 2018;27(8):845–57.
4. Reina-Campos M, Diaz-Meco MT, Moscat J. The dual roles of the atypical protein kinase Cs in cancer. Cancer Cell. 2019;36(3):218–35.
5. Khan K, Shah H, Rehman A, Badshah Y, Ashraf NM, Shabbir M. Influence of PRKCE non-synonymous variants on protein dynamics and functionality. Human Mol Genet. 2022;31(13):2236–61.